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Colorectal cancer is the third most common type of cancer worldwide and the fourth most common cause of 
death. It is a disease that progresses through a series of steps, resulting from modifications in both genetic and 
epigenetic mechanisms. Despite significant advancements in treatment options, colorectal cancer patient survival is 
still poor owing to a lack of effective tools for early diagnosis and a limited capacity for optimal therapeutic decision 
making. 
Growing evidence suggests an important role of epigenetic modifications in human cancer, including colorectal 
cancer, affecting every aspect of tumor progression, from initiation to metastasis. Epigenetic modifications related to 
DNA methylation have already been extensively studied in the context of cancer. However, the presence and clinical 
relevance of other modifications such as histone post-translational modifications and especially chromatin 
remodelers have only more recently started being explored and the results are still limited, but very promising.  
The understanding of these mechanisms has contributed to the identification of new epigenetic biomarkers 
relevant to clinical practice, allowing for the optimization of diagnostic, prognostic and therapeutic response 
monitoring systems, as well as the generation of novel and targeted therapeutic approaches.  
This review aims to present current understanding of the altered patterns of histone modifications and 
expression of chromatin remodelers in colorectal cancer, focusing on their potential clinical applications, especially 
the possible use of some of them as epigenetic biomarkers for early detection, management and risk estimation of 
colorectal cancer. The possibility of using epigenetic silencing as a therapeutic target in colorectal cancer is already 
being explored and will also be addressed here. Lastly, some challenges and future perspectives in this field of 
epigenetics will be presented, as a possible way to improve clinical outcome in patients with colorectal cancer. 
 
Resumo 
O cancro colo-retal é a terceira neoplasia maligna com maior incidência e a quarta causa mais comum de morte 
por cancro a nível mundial. É uma patologia que se desenvolve através de vários passos, resultando de alterações em 
mecanismos genéticos e epigenéticos. O prognóstico do cancro colo-retal é ainda bastante reservado, pela falta de 
ferramentas eficazes para diagnóstico precoce e pela capacidade limitada de terapêutica curativa. 
Evidências crescentes apontam para um papel importante das alterações epigenéticas no cancro humano, 
incluindo o cancro colo-retal, afetando todos os aspetos do desenvolvimento tumoral, desde a iniciação, progressão 
e à metastização. Alterações epigenéticas associadas à metilação do DNA já foram extensamente estudadas no 
contexto do cancro. Contudo, a presença e relevância clínica de outras alterações como as modificações pós-
traducionais de histonas e sobretudo a desregulação da expressão dos remodeladores da cromatina têm sido 
avaliadas apenas mais recentemente e os resultados são ainda limitados, mas promissores. 
O aumento do conhecimento destes mecanismos tem contribuído para a identificação de novos biomarcadores 
epigenéticos com impacto na prática clínica, permitindo a otimização dos sistemas de diagnóstico precoce, 
prognóstico e monitorização da resposta terapêutica, bem como o desenvolvimento de novas abordagens 
terapêuticas mais dirigidas.  
Neste artigo de revisão, será abordada a desregulação dos padrões de modificação de histonas e de expressão 
de remodeladores da cromatina no cancro colo-retal. Será dado especial ênfase ao potencial de aplicação dessas 
alterações na prática clínica, nomeadamente através da possibilidade de utilização de algumas delas como 
marcadores epigenéticos para deteção precoce do cancro colo-retal, avaliação da agressividade e do risco de 
metastização e estimação do prognóstico. Serão ainda avaliadas as potencialidades do recurso a silenciamento 
epigenético como alvo terapêutico no cancro colo-retal. Por último, será feita uma consideração sobre as perspetivas 
futuras neste campo da epigenética para a abordagem clínica do cancro colo-retal. 
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The writing of this review involved an extensive search of review and original articles published on the subject 
of epigenetics of colorectal cancer. This search was conducted online, using the free search engine PubMed. The 
following expressions were used to find relevant references: “histone modification in colorectal cancer”, “histone 
acetylation in colorectal cancer”, “histone methylation in colorectal cancer”, “chromatin remodelers in colorectal 
cancer”, “epigenetics in colorectal cancer”, “epigenetic biomarkers in colorectal cancer”. Some other expressions 
were used to conduct a more specific search to complement the findings in the articles retrieved with the more 
general search criteria. For example, the expressions “ARID1 colorectal cancer”, “EZH2 colorectal cancer” and “CHD5 
colorectal cancer” were used to look for more recent works with these epigenetic markers. Additionally, some articles 
were also found through reading of previous reviews on the subject, including the ones by Huang et al. (2017), Gezer 
and Holdenrieder (2014), Jia and Guo (2013) and Bardhan and Liu (2013). 
Articles that matched the search criteria and were clearly related to the theme of this review were selected 
according to their year of publication (only articles published after 2005 were included in this review, except in specific 
situations) and relevance to the aims of this review. Some importance was also given to the impact of these articles, 
measured by the number of citations. Articles were also preferentially selected according to the position in which 
they appeared in the search results in PubMed, when using the sorting option “Best Match”.  
 
1. Introduction: CRC epidemiology and clinical management 
Colorectal cancer (CRC) is the third most common type of cancer worldwide and the fourth most common cause 
of death (Haggar and Boushey, 2009). Globally, CRC is the third most commonly diagnosed cancer in males and the 
second in females, with 1,4 million new cases and almost 694 000 deaths estimated to have occurred in 2012 (Torre 
et al., 2012).The highest incidence rates are in Australia/New Zealand, Europe, and Northern America. Rates are low 
in Africa and South-Central Asia.  
CRC clinical management can benefit from different strategies depending on its stage: health promotion through 
health education campaigns (when the disease is not yet present), the implementation of screening programs (for 
the detection of the disease in its early stages), and the development of nearly personalized treatments according to 
both patient characteristics (age, sex) and the cancer itself (gene expression) (Binefa et al., 2014). 
Preventive measures for colorectal cancer include maintaining a healthy body weight, being physically active, 
minimizing consumption of red and processed meat and alcohol, and avoidance of smoking (Botteri et al., 2008; 
Ferrari et al., 2007; Giovannucci and Wu, 2006). Screening can detect colorectal polyps that can be removed before 
they become cancerous, as well as detect cancer at an early stage when treatment is usually less extensive and more 
successful. There are several accepted screening options (eg, the guaiac-based fecal occult blood test [FOBT], the 
immunochemical FOBT [or fecal immunochemical test], flexible sigmoidoscopy, stool DNA test, computed 
tomography [CT] colonography [“virtual colonoscopy”], double-contrast barium enema, and colonoscopy). 
Despite advancements in treatment options, improvements in patient survival for CRC have been limited due to 
lack of early detection (Rawson and Bapat, 2012). Although some of the CRC screening tests available have proven to 
be effective in the reduction of incidence and mortality, a highly specific, noninvasive detection method has yet to be 
discovered. Molecular tests are expected to be more sensitive and specific than current methods. They will also 
provide genetic information about the malignancy in progression (Coppedè et al., 2014a).  
The ideal molecular marker should have the following features: it should have high sensitivity and specificity; it 
should be safe and affordable so that it can be broadly accepted by patients; it should be easy to measure; and it 
should be consistently detected across genders and ethnic groups (Kumar, 2009; Huang et al., 2010; Parik and Vasan, 
2007; Tanaka et. al, 2010). A robust biomarker should detect genomic/epigenomic alterations and/or variations in 
protein expression that specifically correlate to the disease helping clinicians make an accurate diagnosis.  
Even if many potential biomarkers have been detected, the number of biomarkers that have been incorporated 
into clinical practice is surprisingly small (Choong and Tsafnat, 2012). Reliable biomarkers are needed to detect CRC 




2. Altered patterns of histone modifications and chromatin 
remodeling in CRC and their clinical relevance 
In a eukaryotic cell, genes are coordinately activated or repressed to ensure cellular homeostasis (Nair and 
Kumar, 2012). In addition to a constant need to modulate the levels of expression of a large number of genes, 
mammalian cells are also faced with a topological challenge of packaging genetic information (about 2 metres of DNA) 
into the nucleus (Clapier and Cairns, 2009). An evolutionary solution to this problem is the unique ability of 
mammalian cells to package the DNA into higher order structures, commonly referred to as chromatin. The basic 
building blocks of chromatin are nucleosomes that are composed of 146 base pairs of DNA wrapped around an 
octamer containing two each of four core DNA packaging proteins - histones H2A, H2B, H3, and H4. The nucleosomes 
are further folded with the aid of linker histone H1 and non-histone proteins into an ordered, compact nucleoprotein 
complex (Saha et al., 2006;Thomas and Kornberg, 1975). Chromatin can be functionally divided into two subtypes, 
euchromatin and heterochromatin. Only about 1.5% of the human genome encodes for genes and very little of this 
coding sequence is present in heterochromatin (Babu and Verma, 1987). 
 
2.1 Chromatin Remodelers 
To fulfill cellular needs, genes that reside in euchromatin are continually undergoing regulated structural 
changes to allow for template-dependent processes like gene activation or repression. These functionally opposite 
events require dynamic packaging and unpacking of DNA elements, and the promoters and enhancers that control 
these events need to be exposed to provide access to regulatory factors and complexes. Hence, expression of genes 
must not only involve the general transcription machinery and specific transcription factors, but also largely depend 
on proteins capable of modifying the chromatin architecture. These unique proteins are called chromatin remodeling 
proteins or remodelers (Cairns, 2001, 2007).  
By consuming ATP-derived energy, these complexes manipulate nucleosomal architecture through the dynamic 
mobilization (insertion/eviction) of nucleosomes as well as the configuration of nucleosomal DNA and histone 
octamers (Dawson and Kouzarides, 2012; You and Jones, 2012; Narlikar et al., 2013). Additionally, chromatin-
remodelers recruit histone modifying proteins and numerous auxiliary proteins in order to construct large scaffolds, 
and participate in complex cross-talk networks with numerous transcription factors (Vaiopoulos et al., 2012). 
To date, four remodeler families have been well characterized they include: SWI/SNF, ISWI, INO80 and 
NuRD/Mi-2. The four remodeler proteins share unifying properties and include (a) Ability to interact with nucleosome 
core, (b) Affinity for post-translationally modified nucleosomal histone-tail residues, (c) Core ATPase activity that 
utilizes energy from ATP hydrolysis to fuel remodeler functions, (d) Regulatory domains that are subject to various 
biochemical and epigenetic alterations, and (e) Specific protein domains and motifs that accommodate protein–
protein interactions. Even though the remodeler proteins share these five basic properties they have evolved 
mechanistically to perform non-overlapping functions (Clapier and Cairns, 2009). Thus remodeler families are 
functionally specialized and have a unique role in regulating distinct transcriptional programs in response to cellular 
cues. 
Chromatin-remodeling complexes orchestrate a wide range of physiological processes including, proliferation, 
self-renewal and differentiation (Vaiopoulos et al., 2012). Since transcriptional control is essential for living processes, 
it is not surprising that genetic alterations in chromatin remodeling components are intimately linked with cancer and 
chromatin remodelers can function as tumor suppressors or promoters depending on contextual signaling (Jones and 
Baylin, 2007; Shain et al., 2012). 
A large number of genomic loci that are repressed in the physiologic state are activated by an aberrant 
expression and/or activity of remodelers in cancerous cells in response to deregulated oncogenic signals (Ellis et al., 
2009). Therefore, deregulation of chromatin leads to altered gene activation and/or inappropriate gene silencing. 
Several tumor suppressors such as retinoblastoma (pRb), p53 and Ini1/hSNF5 which utilize chromatin remodeling as 
part of its normal functions are misregulated in certain cancers (Gregory and Shiekhattar, 2004; Hickman et al., 2002).  
In colorectal cancer, nucleosomal insertion in the promoter CpG island region may facilitate epigenetic gene 
silencing through heritable modifications in chromatin conformation, as in the case of MLH1 (Lin et al., 2007). 
Similarly, distant Wnt-related responsive enhancers may reach and up-regulate c-Myc, a pivotal coordinator of 
proliferation and apoptosis in CRC, through the generation of large chromosomal loops (Yochum, 2011). More recent 
experimental data link the upregulation of vascular endothelial growth factor (VEGF) by peroxisome proliferator 
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activated receptor δ (PPAR-δ) through a mechanism that involves β-catenin-mediated chromatin looping (Hwang et 
al., 2012). 
Overexpression or mutated forms of several members of the remodeling machinery have been identified in a 
broad range of hematological and solid malignancies, including CRC. 
SWI/SNF chromatin remodeling complex regulates critical cellular processes including cell cycle progression, 
programmed cell death, differentiation, genomic instability and DNA repair (Narlikar et al., 2013). The SWI/SNF 
complex, containing one of 2 mutually exclusive ATPase subunits, BRG1/SMARCA4 or BRM/SMARCA2, physically 
alters nucleosome positioning using energy generated by ATP hydrolysis (Jaclyn et al., 2014). The complexes can be 
subdivided into two broad categories, BAF or PBAF, based upon the presence of the ARID1A/B subunits, or ARID2 and 
PBRM1 subunits, respectively (Kadoch et al., 2013; Wei and Weissman, 2014).  
In CRC, SWI/SNF complex seems to be involved in multiple aspects of development and progression. For 
instance, BRG1 is implicated in the promotion of metastasis through a mechanism involving the down-regulation of 
E-cadherin (Sanchez-Tillo et al., 2010). Expression of BRG1, but not BRM, was found to be frequently elevated in CRC 
specimens by Watanabe et al. (2011). They also found that PTEN expression was negatively regulated by BRG1, which 
subsequently influenced the cyclin D1 levels via the PI3K–Akt signalling pathway. Shengtao et al. (2016) showed 
increased expression of BRG1 was associated with AJCC stage, depth of tumor invasion, distant metastasis, and 
histologic differentiation in colon cancer. These results indicated that BRG1 is closely correlated with aggressive 
malignant behavior and its presence predicts poor survival for colon cancer patients. BRG1 failed to act as an 
independent prognosis predictor on multivariate analysis but, in collaboration with other biomarkers, BRG1 
expression levels could be taken into consideration when making treatment decisions. Patients with elevated BRG1 
expression require more powerful adjunctive treatments and frequent postoperative follow-up, which serves as a 
profound guide in clinical treatment. Additionally, Zhu et al. (2016) demonstrated the important roles of the 
BRG1/STAT3/VEGFC in tumor-associated lymphangiogenesis, which might lead to the discovery of novel therapeutic 
targets in the treatment of CRC. 
Inactivating mutation of several other SWI/SNF members is also a frequent event in CRC patients (especially 
with MSI), including ARID1A (Network, 2012) and SMARCC2 (Kim et al., 2013).  All the 15 genes of the ARID gene 
family contain the ARID domain, which is known to be centrally involved in chromatin regulation (Patsialou et al., 
2005; Wang et al., 2004). Frequent inactivating mutations in ARID1A have been identiﬁed in a wide variety of cancers, 
including CRC, and it has been recognized as a novel tumor suppressor gene (Wu and Roberts, 2013). As already 
shown by Jones et al. (2012), Cajuso et al. (2014) conﬁrmed that ARID1A is frequently mutated also in MSI CRC. Their results 
further suggested that, based on their mutation frequency, ARID1B, ARID2 and ARID4A should be considered new 
candidate genes for MSI CRC. Lee et al. (2016a) showed that cases with ARID1A loss were associated with poor 
differentiation, lymphovascular invasion and higher pT stage. However, at a median follow-up of 49 months, ARID1A 
loss did not correlate with overall, disease-specific, or recurrence-free survival. These data indicated that ARID1A loss 
lacks prognostic significance in the studied population, despite its association with other adverse features. Another 
study, however, concluded that, specifically among the mismatch repair(MMR)-deficient cases, ARID1A loss 
correlated with medullary histology and an increased rate of nodal and distant metastasis and these patients also 
tended toward a worse 5-year overall survival (Ye et al., 2014).  
SMARCB1 is also a core component of the BAF (hSWI/SNF) complex and its negative expression (found in 11% 
of CRCs) was associated with poor differentiation, liver metastasis and shorter patients' survival regardless of the 
MMR status or tumor stage (Pancione et al., 2013). 
CHD5 belongs to a group of SWI/SNF proteins called chromodomain helicase DNA binding (CHD) proteins, which 
contain a SWI/SNF-like/ATPase domain, and some members form a nucleosome remodeling and deacetylation 
complex that directly modifies chromatin structure and enhances the binding of transcription factors to their binding 
sites (Thompson et al., 2003). As such, CHD5 has an impact on gene regulation, and it was shown to be highly 
methylated in colon cancer tumors of African American patients (Mokarram et al., 2009). Fatemi et al. (2015) showed 
that the CHD5 gene is repressed in all types of adenomas, either epigenetically or by chromosomal deletion. As such, 
CHD5 likely acts as a tumor-suppressor gene in early colorectal carcinogenesis.  
Moreover, other studies suggest that the expression of other members of the chromodomain 
helicase/adenosine triphosphate-dependent chromatin remodeling family was also altered in CRC. Tahara et al. 
(2014) showed that genes that regulate chromatin were mutated in CIMP1 CRCs and the highest rates of mutation 
were observed in CHD7 and CHD8. Kim et al. (2011) detected mutations in the CHD8 gene in 28.6% of the MSI-H CRCs, 
with loss of expression. 
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Another chromatin-remodeler, nucleosome remodeling and histone deacetylase (NuRD), determines the fate 
of various signaling pathways (Vaiopoulos et al., 2012). NuRD is responsible, at least in part, for the repression of the 
transcriptional activity of AP-1 transcription factor. AP-1 possesses a pivotal role in the orchestration of intestinal 
proliferation and the promotion of tumorigenesis (Aguilera et al., 2011). NuRD however is also involved in the 
silencing of tumor suppressor genes, such as negative regulators of Wnt, often in synergy with DNMTs (Cai et al., 
2013). In accordance to this data, immunohistochemical analysis of surgically resected colorectal tumors correlated 
the positive expression of HDAC1 and MTA1, two NuRD members, with decreased overall survival and poor clinical 
outcome (Higashijma et al., 2011). Cai et al. (2014) established an oncogenic role for CHD4, another NuRD component, 
for initiating and supporting tumor suppressor gene (TSG) silencing in human colorectal cancer. In their study, CHD4 
knockdown activated silenced TSGs, revealing their role for blunting colorectal cancer cell proliferation, invasion, and 
metastases. In another study, high CHD4 levels plus low expression of TSGs strongly correlated with early disease 
recurrence and decreased overall survival. Since CHD4 has ATPase activity, this data identified CHD4 as a potentially 
novel drug target in cancer (Xia et al., 2017). 
Special AT-rich sequence-binding protein 1 and 2 (SATB1/2) are nuclear matrix-associated proteins also involved 
in chromatin remodeling and regulation of gene expression. Mansour et al. (2016) concluded that SATB1 expression 
was increased, whereas SATB2 expression was reduced, in colorectal cancer tissues compared to control tissues. 
Brocato et al. (2015) presented four major conclusions regarding the role of these proteins in CRC and their potential 
clinical value as biomarkers in CRC: (i) SATB2 is a sensitive marker to distinguish CRC from other cancer types, (ii) 
Reduced expression of SATB2 in CRC is associated with poor prognosis, (iii) High levels of SATB1 expression facilitate 
CRC and are associated with poor prognosis. 
The Tip60 histone acetyltransferase is implicated in DNA-damage response, exerts anti-proliferative effects and 
represses the Wnt-pathway. It belongs to a multi-molecular complex that contains many chromatin remodeling 
enzymes including the ATPase p400, a protein involved in nucleosome incorporation of specific histone variants and 
that can directly or indirectly repress some Tip60-dependent pathways, up-regulating Wnt. Tip60 activity is critical 
for the cellular response to DNA damage and is affected during cancer progression. Mattera et al. (2009) found that 
the ratio between Tip60 and p400 mRNAs is affected in most colorectal carcinoma and is critical for the response to 
5-fluorouracil, a first-line treatment against colon cancer. These results were supported by Chevillard-Briet et al. 
(2013), which confirmed that, In CRC, the ratio of Tip60/p400 is unbalanced in favor of p400 and promotes Wnt 
activity and carcinogenesis. The results of another study suggested that Tip60 was more frequently down-regulated 
in advanced colorectal carcinoma and could serve as a potential marker for the malignancy of CRC (Sakuraba et al., 
2009)  
HELLS (also known as SMARC6 and LSH) gene encodes a protein related to the SNF2 family of chromatin-
remodeling ATPase. This protein is essential for correct establishment of DNA methylation level and for efficient repair 
of DNA double-strand breaks. Choi et al. (2015) observed aberrant bands of the HELLS gene in eight cancers (seven 
CRC and one GC). DNA from normal tissue showed no shifts in SSCP (single-strand conformation polymorphism), 
indicating the aberrant bands had risen somatically, indicating a possible role of HELLS as a TSG in CRC. 
One study also revealed that BPTF, a chromatin remodeling-related gene, exhibits frameshift mutations in 
gastric and colorectal cancers (Lee et al., 2016b). 
Table 1 (see Annex I) presents a summary of the chromatin remodelers found to have an altered expression in 
CRC and possibly associated with tumorigenesis and, in some cases, also associated with clinical outcomes. 
 
2.2 Histone post-translational modifications 
In addition to ATP-dependent chromatin remodelers, the core nucleosome histone structures have a unique 
role in determining chromatin architecture. Interaction of histone proteins H2A, H2B, H3 and H4 with nucleosome 
DNA has a special relevance in chromatin biology as these interactions regulate an overall affinity of nucleosome 
histones with DNA, leading to a relaxed or condensed chromatin.  
The four core histones are subject to a plethora of post-translational modifications that are inscribed by histone-
modifying enzymes and multiple modifications, such as phosphorylation, acetylation, methylation, ubiquitination and 
citrulation (Peterson and Laniel, 2004). While it is believed that post-translational modifications of histone-tails and 
residues within globular histone can alter nucleosome mobility, some studies have demonstrated that a combinatorial 
pattern of histone modification may constitute an epigenetic code to be recognized, interpreted or modified by other 
chromatin binding proteins with specialized histone binding domains (Berger, 2002). Binding of effector proteins to 
modified histone modules are important for full transcriptional outcomes. It has been demonstrated that the 
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epigenetic language, or “histone code”, acts as a molecular beacon and might offer a bird's eye view of the chromatin 
landscape for transcription factors and coregulatory proteins with roles in gene expression or repression (Strahl and 
Allis, 2000). Therefore, histone's post-translational modifications increase capacity of genome to store and/or 
transmit biologic information. 
Modifications of histone tail in the steady or dynamic-state of chromatin are tightly controlled by histone 
modifying enzymes and perturbations in such components are often associated with cancer. In contrast to 
methylation-associated alterations, the understanding of histone modification patterns in human cancers and their 
correlation with the CIMP status and the different CRC pathways is limited (Goel and Boland, 2012) and the best 
studied histone modifications in CRC are acetylation and methylation of lysine and arginine residues within histone 
tails. 
 
2.2.1- Histone acetylation: players and patterns 
Histone acetylation is reversible modifications of lysine residues on histone “tails” and is controlled by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) that typically act as transcriptional co-activators or co-
repressors, respectively. Of all the known modifications, acetylation has the most potential to unfold chromatin since 
it neutralizes the basic charge of the lysine (Coppedè, 2014b). HATs are divided into three main families: GNAT, MYST 
and CBP/p300. Most of the acetylation sites characterized to date fall within the N-terminal tail of histones, which 
are more accessible for modification. The reversal of acetylation correlates with transcriptional repression. There are 
three distinct families of HDACs: the class I and class II HDACs and the class III NAD-dependent enzymes of the Sirt 
family (Weichert et al., 2008). They are involved in multiple signaling pathways and they are present in numerous 
repressive chromatin complexes. In general, these enzymes do not appear to show much specificity for a particular 
acetyl group. In cancer cells, disruption of the balance between HATs and HDACs contributes to transcriptional 
inactivation of tumor suppressor genes (TSGs) (Fraga et al., 2005; Seligson et al., 2005). 
Several investigators observed global H3 and H4 lysine hypoacetylation in CRC cell lines and primary tumors, 
including CRC, often associated with downregulation of tumor suppressor genes and metastasis suppressor genes 
(Gargalionis et al., 2012). Fraga et al. (2005) found global loss of H4K16ac in cancer cells and primary tumors, including 
colonic tumors. Subsequent studies investigated the global pattern of individual histone marks, mainly by 
immunohistochemistry. Two different studies reported that global levels of H4K12ac and H3K18ac increased in 
adenocarcinomas in respect to normal tissue or adenoma (Ashktorab et al., 2009; Nakazawa et al., 2012). Acetylation 
of H3K9 (H3K9ac) correlated with the tumor histological type (Tamagawa et al., 2012).  
Alterations in HDACs are found in many human cancers including CRC (Marks et al., 2001). Multiple class I HDACs 
are up-regulated in a subset of CRCs, including HDAC1 in 36.4%, HDAC2 in 57.9%, and HDAC3 in 72.9% of CRC 
specimens, and high HDAC2 expression has been shown to be associated with reduced patient survival in CRC 
(Ashktorab et al., 2009). In particular, HDAC2 upregulation was found early in colon field carcinogenesis (Stypula-
Cyrus et al., 2013). Nuclear expression of HDAC2 was observed in 81.9% of colorectal carcinoma, 62.1% colorectal 
adenoma and 53.1% of normal tissues, respectively (Ishihama et al., 2007). The overexpression of HDAC2 was 
found to be accompanied by the hypoacetylation at H4K12 and H3K18 histones during adenoma to carcinoma 
progression, contrarily to what was observed in other studies. Upregulation of several class II (HDAC5 and HDAC7) 
and class III (sirtuins) HDACs has also been observed in CRC, and linked to downregulation of genes involved in the 
Wnt signaling pathway (Rönsch et al., 2011; Stypula-Cyrus et al., 2013). HDAC4 missense mutations have been 
observed and HDAC4 has been shown to be downregulated in colon cancers (Bassett and Barnett, 2014). In CRC, 
Bassett and Barnett (2014) also reported an HDAC5 downregulation but an HDAC7 overexpression. The class III 
HDAC, SIRT1, is shown to be overexpressed in 40% of CRCs associated with CIMP-high and MSI-H tumors in a study 
of 485 CRC cases (Nosho et al., 2009). Inhibition of SIRT1 can reactivate the transcriptionally silenced genes, 
suggesting a possible therapeutic approach to reverse epigenetic alteration-induced silencing process of many 
genes (Strahl and Allis, 2000).  
CREB-binding protein (CBP)/p300 and their associated factor (PCAF) facilitate the effects of β-catenin through 
acetylation (Chevillard-Briet et al., 2013). Strikingly, the role of p300 in CRC has not yet been elucidated as its 
overexpression has been associated with advanced tumor stages, metastasis and poor clinical outcome (Ishihama et 
al., 2007), while other research groups have linked p300 expression with increased survival (Huh et al., 2013). p300 
binds to and acetylates MTA2, a member of metastasis associated family proteins, and this is seems to be important 
for CRC cells growth and migration (Zhou et al., 2014). 
Human MOF (males absent on the first) is a member of the MYST (Moz-Ybf2/Sas3-Sas2-Tip60) family of histone 
acetyltransferases (HATs). As a catalytic subunit, MOF can form at least two distinct multiprotein complexes (MSL and 
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NSL) in human cells. Both complexes can acetylate histone H4 at lysine 16 (H4K16); however, the NSL complex 
possesses broader substrate specificity and can also acetylate histone H4 at lysines 5 and 8 (H4K5 and H4K8). Silencing 
of MOF in cells leads to genomic instability, inactivation of gene transcription, defective DNA damage repair and early 
embryonic lethality. Unbalanced MOF expression and its corresponding acetylation of H4K16 have been found in 
certain primary cancer tissues, including colorectal carcinoma (Su et al., 2016). 
 
2.2.2- Histone methylation, players and patterns 
Histone methylation is other most frequent post-translational modification that occurs both on lysine and 
arginine residues of the N-terminal tail of histones. Like histone acetylation, histone methylation is now appreciated 
as a reversible process (Bannister et al., 2011). Its homeostasis is mediated by two antagonizing groups of enzymes, 
histone methyltransferases (HMTases) and histone demethylases (HDMs), which install and remove histone 
methylation marks, respectively, in a site-specific manner (Klose and Zhang, 2007). To date, more than twenty lysine 
and arginine HMTases have been identified. Each of the HMTases, either acting alone or in complex with other 
HMTases, catalyzes site-specific histone methylation. For histone H3, methylation has been observed at multiple 
lysine sites, including H3K4, K9, K27, K36 and K79, and addition of up to three methyl groups at each lysine produces 
a total of four methyl states: unmethylated, monomethylated, dimethylated and trimethylated. H3K4 trimethylation 
(H3K4me3) is strongly associated with transcriptional competence and activation, with the highest levels observed 
near transcriptional start sites of highly expressed genes. Two other methylation sites on histones, H3K36 and H3K79, 
are implicated in activation of transcription (Vakoc et al., 2006). On the contrary, H3K27 trimethylation (H3K27me3) 
is frequently associated with gene silencing (Barski et al., 2007). Two other lysine methylation sites that are connected 
to transcriptional repression are H3K9 and H4K20 (Kouzarides, 2007). The establishment of an appropriate pattern of 
histone methylation is not only crucial for normal development and differentiation, but is also intimately associated 
with tumor initiation and development. Histone methylation at key lysine residues has been shown to work in concert 
with acetylation and other modifications to provide a histone code that may determine heritable transcriptional 
states (Jenuwein and Allis, 2001).  
Changes in histone lysine methylation status have been observed during CRC formation, which is thought to be 
a consequence of dysregulation of histone lysine methyltransferases or the opposing demethylases (Berry and 
Janknecht, 2013). It has been shown that several of these changes in methylation status correlate with pathological 
features of CRC, such as tumor size, histological type and tendency to lymph node invasion and distant metastasis. 
Methylation of histone tails has been largely documented in CRC primary tumors and cell lines, including loss of tri-
methylation of H4K20, and di- and tri-methylation of H3K9 (H3K9me2/me3), H3K4 (H3K4me2/me3) and H3K27 
(H3K27me2/me3)(Gargalionis et al., 2012; Fraga et al. 2005) found global loss of H4K20me3 in cancer cells and 
primary tumors, including colonic tumors. Later studies revealed that H3K9me2 expression was associated with the 
progression of adenoma to adenocarcinoma. The global level of H3K9me2 was distinctly higher in neoplastic cells 
(adenoma and adenocarcinoma) than in normal glandular cells; in addition, it was significantly higher in 
adenocarcinoma than in adenoma and was specifically increased in invasive regions of CRC tissues (Yokoyama et al., 
2013). Moreover, the presence of H3K9me3 positively correlated with lymph node metastasis in patients with CRC 
(Nakazawa et al., 2012). However, H3K9me3 and H4K20me3 have been found to be almost absent at the 
pericentromeric satellite II repeat in patients with CRC when compared with healthy controls or patients with multiple 
myeloma (Gezer et al., 2011; Leszinski et al., 2012a). More recently, through next-generation sequencing of 
immunoprecipitated plasma DNA, (Gezer et al., 2013) confirmed reduced levels of H3K9me3 and H4K20me3-related 
repetitive sequences in circulation of patients with CRC. Consistently, high expression of H4K20me3 and H3K9me3, 
and low nuclear expression of H3K4me3, were associated with good prognosis in early-stage CRC patients (Benard et 
al., 2014). 
As a well-known gene activation marker, H3K4me3, was found to be elevated in tumor tissue of CRC patients 
and several cell lines, resulting in activated expression of WNT-signaling target genes through interaction between 
SET Domain containing 1A (SETD1A) and of β-catenin (Salz et al., 2014). Interestingly, H3K4me1/2/3 were all 
decreased at the MutL Homolog 1 (MLH1) promoter in SW480 cells under hypoxia, leading to silence of MLH1 and 
DNA mismatch repair defects, a key process in the development of sporadic CRC (Lu et al., 2014). Additionally, 
dimethylation of H3K4 (H3K4me2) correlated with the tumor histological type and lower levels of H3K4me2 
correlated with a poor survival rate. The multivariable survival analysis showed that H3K4me2 status is an 
independent prognostic factor for patients with CRC (Tamagawa et al., 2012). The transcription-repression marker 
H3K27me3 was found to be increased in tumor tissue of CRC patients with poor prognosis (Benard et al., 2013, 2014). 
In addition, it has been found that the methylation level of H3K27me2 detected with immunohistochemistry is an 
independent prognostic factor for metachronous liver metastasis of colorectal carcinomas (Tamagawa et al., 2013). 
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Lastly, dimethylation of histone 3 lysine 79 (H3K79me2) was elevated in CRC patients with poor prognosis, enhancing 
IL-22-induced cancer stemness (Kryczek et al., 2014). 
Among the writers and erasers of these methylation marks, the polycomb repressive complexes PRC1 and PRC2 
mediate epigenetic silencing of several tumor suppressor genes in cancers via histone methylation. PRC1 binds at 
H3K27me3 and possesses histone-ubiquitylation abilities. The histone methyltransferase enhancer of Zeste 2 (EZH2) 
is the central unit of PRC2, responsible for H3K27me3 (Simon and Kingston, 2009). PRC1 and PRC2 may cooperate for 
gene repression or act in an independent manner (Varier and Timmers, 2011; Richly et al., 2011). Polycomb proteins 
coordinate crucial developmental steps and their malfunction is often observed in various malignancies. Both PRC1 
and PRC2 interact with DNMTs and are believed to play a fundamental role in transcriptional gene silencing in CRC 
(Ohm et al., 2007). In vitro evidence from CRC cells indicate the involvement of EZH2 in tumor proliferation and 
growth (Fussbroich et al., 2011). The PRC protein EZH2 is frequently found to be overexpressed in various solid 
tumors, including colon cancer (Simon and Lange, 2008; Bracken and Helin, 2009; Liu et al., 2015). The oncogenic 
function of EZH2 has been mechanistically attributed to the silencing of tumor suppressor genes, including  INK4B-
ARF-INK4A, p57 KIP2, p27 (Gonzalez et al., 2009), BRCA1 (Yu et al., 2007) and adrenergic receptor β2 (Natarajan et 
al., 2010). PRC1 and PRC2 complexes are implicated in metastasis through their ability to repress E-cadherin via B 
lymphoma Mo-MLV insertion region 1 homolog (Bmi1) and EZH2 respectively (Lee et al., 2012). Bmi1 and other 
members of the polycomb group family have been found elevated in CRC patients and have been correlated with 
advanced stages and aggressive types of carcinomas (Du et al., 2010).  
Recent experimental data reveal other links between HMTs and key regulatory signaling pathways. KMT2B/ 
MLL4, KMT2D/MLL2, and SETD1A are all H3K4 methyltransferases that promote the development of CRC (Denissov 
et al., 2014; Nguyen et al., 2008; Nightingale et al., 2007). MLL2, an epigenetic regulator in mammalian cells, mediates 
histone 3 lysine 4 tri-methylation (H3K4me3) through the formation of a multiprotein complex. Elevated MLL2 
expression level has been observed in poorly differentiated and more invasive colon carcinoma cell lines, and in 
colon carcinoma tissues as compared to the corresponding adjacent normal colonic epithelium (Kang et al, 2007). 
MLL2 is primarily regarded as a nuclear protein with nuclear localization signal. Colonic cell lines derived from 
highly invasive tumors, exhibited altered sub-cellular distribution and proteolytic processing of MLL2 compared to 
the non-tumor/less invasive tumor cell lines. Mixed lineage leukemia-4 (MLL4) regulates the expression of various 
cyclins, p-proteins and HOX genes that are critical players in cell-cycle progression, via histone H3K4 trimethylation in 
the target gene promoters (Ansari et al., 2012). Natarajan et al. (2010) showed that knockdown of MLL4 resulted in 
cell-cycle defect and induced apoptosis in colon cancer cells. Further, MLL4/KMT2D was found to be significantly 
elevated in tumor tissue compared with adjacent benign mucosa in CRC patients’ samples and cell lines. Levels of 
SETD1A were elevated in human CRC cells and patient samples; while depletion of SETD1A inhibited CRC cell growth 
and affected about 50% WNT target genes (Salz et al., 2014). 
Interestingly, H3K4 demethylases, KDM1A/LSD1 and KDM5B/JARID1B (Secombe and Eisenman, 2007), like H3K4 
HMTs, also promote the development of CRC, suggesting that the local H3K4 methylation profile might be better 
associated with CRC. JARID1B is involved in CRC maintenance, and depletion of JARID1B led to loss of epithelial 
differentiation and suppression of CRC cell growth (Ohta et al., 2013). Lysine specific demethylase 1 (LSD1) seems to 
potentiate proliferation, invasiveness and metastatic potential of CRC cells (Ding et al., 2013). LSD1 has been positively 
correlated with TNM stage, lymph node infiltration and metastatic disease in CRC patients (Jie et al., 2013). 
SUV39H1 is an HMTase, which specifically methylates H3K9 at the pericentric heterochromatin. Tiwari et al. 
(2008) found elevated SUV39H1 expression level in 54 of 219 CRC patients specimens examined. EHMT2/G9a is also 
responsible for dimethylation of H3K9 (H3K9me2). Recently, EHMT2 was found to be much higher expressed in CRC 
tumor tissue than peritumoral counterparts, with a possible role in CRC tumorigenesis (Zhang et al., 2015b). 
Takada et al. (2007) noticed that NLK, known to antagonize WNT signaling, phosphorylates SETDB1, a histone 
methyltransferase, leading to the formation of a corepressor complex that inactivates the activity of the 
transcriptional factor PPARγ through histone 3-K9 methylation in CRC. This suggests that NLK and SETDB1 affect 
Notch-mediated inhibition of WNT target gene expression by modifying histone status in CRC in this tumor type (Kim 
et al., 2012).  
KDM4B and KDM4C are both demethylases of H3K9. High expression of KDM4B was correlated with lymph node 
status, Duke’s classification and tumor invasion of CRC patients (Liu et al., 2013). Consistent with this finding, KDM4B 
was upregulated in colon and rectal adenocarcinomas (Berry et al., 2014). KDM4C overexpression was found in colon 
cancer cell lines, whereas KDM4C downregulation associated with reduced growth and clonogenic capacity of colon 
cancer cells (Kim et al., 2014). These results support both KDM4B and KDM4C as oncoproteins in CRC. 
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DOT1L is an activator of the Wnt-dependent transcription in CRC cells (Simon and Lange, 2008). DOT1L is the 
only non-SET-domain-containing PKMT that methylates H3K79 (Steger et al., 2008). High expression of DOT1L in CRC 
tissue is a predictor for poor prognosis (Kryczek et al., 2014). 
Other HMTs overexpressed in CRC include: SMYD3, the methyltransferase of H4K5 (Van Aller et al., 2012); 
WHSC1/MMSET/NSD2, responsible for the methylation of H4K20, and whose expression level was correlated with 
tumor aggressiveness (Hudlebusch et al., 2011); CARM1/PRMT4, which methylates H3R17 and H3R26 (Ou et al., 
2011); PRMT5, which catalyzes symmetric dimethylation on histone 3 arginine 8 (H3R8me2s) and histone 4 arginine 
3 (H4R3me2s) and induces transcriptional repression and has been associated with poor patient survival (Zhang et 
al., 2015a). 
Recently, direct mutations in histone-methylation sites have also been found to contribute to abnormal histone-
methylation profile, then cancer development. Histone 3 lysine 36-to-methionine (H3K36M) mutation was identified 
in a CRC sample (Shah et al., 2014). This mutation has been proved to impair mesenchymal progenitor cell 
differentiation and promote undifferentiated sarcoma in vivo (Lu et al., 2016), suggesting that H3K36 methylation is 
an important epigenetic marker for tumor suppression.  
Apart from the widely studied histone modifications, ubiquitination may serve as an alternative mechanism of 
gene regulation in CRC. Histone ubiquitination can be associated with both gene silencing and activation. It has been 
shown that an H2B ubiquitin ligase is mutated in various solid tumors including CRC, whereas an H2B deubiquitinase 
has been reported to be overexpressed in colorectal and breast cancer (Johnsen, 2012). Recently, loss of H2B 
monoubiquitination has been linked with the abnormal cancer cells’ glucose metabolism, which permits survival in 
adverse conditions (Urasaki et al., 2012). In vitro and in vivo data point out that histone 2A ubiquitination, mediated 
by the PRC1 complex member Bmi1, is actively involved in the proliferation of CRC cells (Yu et al., 2012). 
In colorectal cancer a high phosphorylated histone H2AX (γH2AX) expression in CRC tissues was associated with 
tumor stage and perineural invasion. Furthermore, a high γH2AX expression was associated with poor distant 
metastasis-free survival (DMFS) and OS. A high γH2AX expression in CRC tissues is associated with a more malignant 
cancer behavior, as well as poor patient survival (Lee et al., 2015). 
Table 2 (see Annex I) presents a summary of the histone post-translational modifications and respective 
regulatory enzymes found to be altered in CRC and possibly associated with tumorigenesis and, in some cases, also 
associated with clinical outcome. 
 
 
3. Epigenetic-based markers for CRC detection, management 
and risk estimation: some considerations 
A sensitive and specific diagnostic marker is not only useful in early diagnosis, but also helps in assessing the risk 
of developing the disease. Advances in the technology have enabled investigators to isolate metabolites, proteins and 
DNA from body fluids and fecal material and correlate them with pathophysiological symptoms of diseases including 
cancer, uncovering a battery of markers for cancer diagnosis; however, only few could reach to clinics because of 
issues of sensitivity and specificity. Therefore, at one side there is a need to improve techniques and on the other 
hand discovery of new markers is of immense importance. Presence of histone proteins is not known in fecal and 
urine samples; therefore, histone posttranslational modifications have been utilized as cancer diagnostic markers 
using circulating nucleosomes (cNUCs) in serum samples (Matei and Nephew, 2010). A blood-based, minimally 
invasive test is seen as a highly attractive approach to increase screening compliance and CRC detection. 
Nucleosomes are released by apoptotic and necrotic cells into the blood circulation. Although macrophages 
efficiently clear dead cells by phagocytosis (Jiang et al., 2003), nucleosomes might enter the circulation reflecting 
either increased production or impaired clearance. In addition to apoptotic and necrotic processes, the active release 
of DNA from all living normal and diseased cells into the bloodstream has also been described (Stroun et al., 2000). 
In patients with cancer, the release of nucleosomes and DNA is elevated due to increased cell turnover 
(Schwarzenbach et al., 2011). Sera of patients with malignant tumors including colorectal cancer showed high levels 
of nucleosome compared with those of healthy persons and patients with benign diseases (Holdenrieder et al., 2001). 
As nucleosomes are stable structures in the circulation (Holdenrieder et al., 2010), they might be a valuable 
source of novel biomarkers (Rahier et al., 2017). However, the diagnostic potential of histone tail modifications in 
CRC is limited if compared with DNA methylation and noncoding RNA biomarkers that can be much more easily 
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detected in circulating blood DNA. Even so, data on the utility of detecting of methylation marks on circulating 
nucleosomes as a novel cancer biomarkers is accumulating.  
Through chromatin immunoprecipitation-associated quantitative PCR, in 2008, the detection of histone 
methylation in blood circulation was carried out (Deligezer et al., 2008). Two histone methylation marks, H3K9me3 
and H4K20me3, the hallmarks of pericentric heterochromatin (Barski et al., 2007), were investigated in circulating 
nucleosomes by subsequent studies. Indeed, H3K9me3 and H4K20me3-related nucleosomes were suggested as CRC 
biomarkers (Gezer et al., 2013). Gezer et al. (2012) investigated the correlation between the H3K9me3 and H4K20me3 
of cNUCs in healthy subjects and patients with colorectal cancer (CRC) and multiple myeloma and found low levels of 
these post-translational modifications (PTMs) in cancer. ChIP based analysis of circulating nucleosomes in serum 
samples by Leszinski et al. (2012b) reported a low level of H3K9me3 and H4K20me3 in patients with colorectal cancer 
compared to healthy control. Moreover, H3K27me3 were found to be significantly lower in CRC patients’ plasma 
than in cancer-free individuals (Gezer et al., 2015). In summary, identification of histone PTMs isolated circulating 
nucleosomes have opened the possibility that blood samples collected can be used for the development of histone 
PTM-based cancer diagnostic marker. However, thus far, these studies are all Phase I biomarker studies. Further 
research is needed to determine whether any of these modifications will be clinically useful diagnostic or prognostic 
biomarkers in CRC. However, histone PTMs have been mostly studied for their potential as prognostic markers in this 
tumor type. As previously mentioned, the report of Fraga et al. (2005) was the first to strongly suggest the utility of 
histone PTMs in cancer diagnosis, showing loss of H4K16ac and H4K20me3 in several cancers, including CRC, and 
establishing these two marks as a hallmark of tumor and establishing the correlation of H4K16ac with tumor 
progression. Tamagawa et al. (2012) has correlated H3K4me2 and H3K9ac with the tumor histological type. In 
addition, lower levels of H3K4me2 and of H3K27me2 associated with poor and were found to be an independent 
prognostic factor. H3K36me3 correlated with lymph node metastasis (Tamagawa et al., 2013). It has also been 
demonstrated that PTMs can exhibit an age-dependent prognostic value in colorectal cancer (Goossens-Beumer et 
al., 2015), where increasing H3K27me3 and H3K9ac with advancing age was found in patients with poor survival or 
outcomes (death/recurrence), compared with decreasing expression in the no-event group. 
More recently, combinations of modifications have been investigated in early stage colon cancer. Low nuclear 
expression of H3K4me3 and high expression of H3K9me3 and H4K20me3 correlated to increased survival and longer 
local and distant recurrence free-survival, especially in  early stage 1 and 2 CRC (Bernard et al., 2014a, 2014b).  
Conversely, a study of H3K27me3 and its associated polycomb proteins EZH2, BMI1 and SUZ12 in CRC indicated 
that an increase in the number of markers showing high expression was associated with better prognosis and revealed 
high expression of all four was correlated with improved overall survival and recurrence-free survival.  
Benard et al. (2014c) also investigated the clinical prognostic value of the histone deacetylases SIRT1, HDAC1 
and HDAC2 and the histone modifications H4K16Ac and H3K56Ac in colorectal cancer. Multivariable trend survival 
analyses of the combined markers showed better patient survival and less tumour recurrence when more markers 
showed high nuclear expression. The studied epigenetic markers showed clinical prognostic value in colorectal cancer, 
both as individual markers and when combined into multimarker analyses.  
Enzymes involved in post-translational modifications of the histone tails may also represent potential prognostic 
biomarkers in CRC, as discussed in the previous section. 
 
 
4. Epigenetic silencing as a therapeutic target in CRC 
Reversible nature of epigenetic changes sms has drawn major attention of scientific community to study the 
molecular mechanism regulating the alteration in epigenetic marks. Such efforts have led to the discovery of several 
histone modifying enzymes and their chemical inhibitors (Cole, 2008), which has emerged as an attractive strategy in 
cancer treatment. Targeting these enzymes can reactivate epigenetically silenced tumor-suppressor genes by 
modulating the levels of histone posttranslational modifications (Espino et al., 2005). Furthermore, these drugs have 
also given additional advantage in the area of combinatorial chemotherapy, especially since there is growing evidence 
supporting the hypothesis that epigenetic alterations may be a driving force of drug resistance in human cancer (Balch 
and Nephew, 2013), a phenomenon that has been reported in many solid tumors, including CRC cells (Arnold et al., 
2003). 
Histone deacetylase inhibitors have undergone major preclinical investigations being also explored for efficacy 
in the treatment of various human cancers in several clinical trials. HDAC inhibitors are promising agents, as in solid 
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tumors they are characterized by relatively low toxicity profile and antiproliferative activities. However, unlike the 
earlier success in treatment of lymphomas the majority of the results among solid tumor patients have been 
disappointing. Indeed, side-effects and the limited clinical efficacy may result from the inability of HDACi to act as 
selective inhibitors (Papavassiliou and Papavassiliou, 2013). 
In colorectal cancer, the current experience is mainly experimental. Histone deacetylase inhibitors are currently 
being admitted as monotherapy or combination therapy either with the conventional chemotherapy or with other 
agents. Valproic acid combined with ionization therapy may enhance tumor response. Vorinostat was the first drug 
of this group used in clinical trial in combination with conventional chemotherapy and managed to stabilize advanced 
colorectal cancer.  
Interactions between different epigenetic mechanisms have led to the foundation of research on combinatorial 
approach of cancer treatment using epigenetic drugs. Indeed, combinations of DNA methyltransferase and histone 
deacetylase inhibitors appear to synergize effectively in the reactivation of epigenetically silenced genes (Cameron et 
al., 1999), allowing for optimal therapy. For example, experimental results show that combination therapy of 
vorinostat and decitabine (DNA methyl transferase inhibitor) in CRC may be more effective than treatment with a 
single therapeutic agent (Yang et al., 2012). Furthermore, combinatorial therapy shows promising results in 
overcoming resistance to conventional agents and in amplifying their effects. Various HDAC inhibitors, including the 
FDA-approved vorinostat, have been shown to effectively sensitize CRC cells to 5-FU-induced apoptosis (Tumber et 
al., 2007; Fazzone et al., 2009). 
In contrast to HDACi, the application of agents targeting histone methylation, HATs and chromatin remodelers 
is still largely unexplored (Bardan and Liu, 2013). However, studies on histone methylation might be more suitable 
because of less redundancy in HMTs and HDM compared to HATs and HDACs in targeting specific amino acid residue 
of histone (Mack, 2010). This property of HMTs and HDMs provides exciting opportunities with more tailored 
treatment, while potentially minimizing side effects. 
Inhibitors of EZH2, DOT1L and other HMTs have demonstrated promising therapeutic effects in preclinical CRC 
treatment (Huang et al., 2017). EPZ00477 is a potent inhibitor of DOT1L and resulted in inhibited sphere formation in 
primary colon cancer (Kryczek et al., 2014). BCI-121, which was identified as SMYD3 inhibitor by virtual screening, 
suppressed the growth of CRC cells (Peserico et al., 2015). Chaetocin is a fungal metabolite that inhibited the activity 
of SUV39H1 and the migration of CRC cells (Yokoyama et al., 2013). BIX01294 and UNC0638 are two potent and 
selective EHMT2 inhibitors that inhibited proliferation of CRC cell lines (Zhang et al., 2015b). DZNep is an indirect 
EZH2 inhibitor, which increased apoptosis in CRC cell lines and colon cancer stem cells (Benoit et al., 2013). EZH2 
inhibitor GSK346 reduced migration of CRC cells (Ferraro et al., 2014). GSK126 is a highly specific inhibitor of EZH2, 
which resulted in reduced level of H3K27me3 (Maryan et al., 2015). AMI-1 is a PRMT5 inhibitor that inhibited 
proliferation of CRC cells in xenograft mouse models (Zhang et al., 2015a). Tranylcypromine, previously used as an 
antidepressant drug, was discovered as a potent LSD1 inhibitor, which suppressed invasion and growth of CRC cells 
(Ding et al., 2013). FLLL-32, one of the curcuminoids, inhibits KDM4C in vitro, resulting in the inhibition of cell 
proliferation of CRC cell lines (Lin et al., 2010). With another EZH2 inhibitor, EPZ-6438, entering into phase I/II trials 
for advanced solid tumors, histone methylation is emerging as a promising target for CRC. Development of more 
selective and potent small molecule modulators of histone-modifying enzymes should be emphasized in the near 
future.  
Other drugs targeting histone modifications with therapeutic potential in CRC include statins, 5-fluorouracil, 
curcumin and compound K. Statins, possibly through EZH2 inhibition, suppress proliferation and induce growth arrest 
of CRC cells (Ishikawa et al., 2013). 5-FU induces global histone de-acetylation in multiple CRC cell lines. Du et al. 
(2017) identified that 5-FU reduces the binding ability of histone acetyltransferases p300 and CBP to chromatin, and 
induces their degradation through lysosome. Curcumin has also been identified as an inhibitor of p300 HAT, inducing 
p300 degradation and inhibiting the acetyltransferase activity of purified p300 (Marcu et al., 2006). Compound K, a 
metabolite of ginseng saponin, induces in exposed HT-29 human colon cancer cells time-dependent inhibition of 
histone deacetylase (HDAC) activity, mRNA and protein expression (Kang et al., 2013; Chen et al., 2016).   
At the preventive level, natural compounds such as folate, epigallocatechin 3-gallate (EGCG) from green tea, 
genistein from soybean, catechol-containing coffee polyphenols and flavonoids seem to lower CRC risk by modulating 
epigenetic modifications. These compounds alter the availability of methyl groups, influence the activity of DNMTs 
and control DNA methylation and histone acetylation (Huang et al., 2011).  
Despite of all this progress in targeting of histone PTMs in cancer patients, little is known about the utility of 
PTMs in monitoring the response to chemotherapy. For this purpose, levels of cNUCs and their modifications can be 
utilized, because circulating nucleosomes in serum are a result of apoptosis of actively dividing cells. Therefore, after 
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chemotherapy/radiotherapy, increase in the circulating nucleosomes correlates with progressive disease, whereas 
decrease was associated with disease regression in several cancers, including CRC. Nucleosome’s concentration 
increase in serum has been shown at 24-72 h after the first application of chemotherapy and 6-24 h after the start of 
radiotherapy (Holdenrieder et al., 2001). Thus, indicating that nucleosomes' levels might be a useful tool for 
monitoring the biochemical responses during antitumor therapy, particularly for the early estimation of therapeutic 
efficacy.  
The discovery that chromatin remodeling complexes regulate gene expression, which deregulation has been 
implicated in cancer has stimulated interest in screening them for small molecule regulators. However, the research 
on chromatin remodelers as targets for cancer therapy, including CRC, is still at a very early phase. Using different 
approaches, two successful screens have been performed to discover small molecule regulators for the BRG1 and 
RUVBL1 ATPases, which inhibited proliferation of cancer cells (Dykhuizen et al., 2012; Elkaim et al., 2012). In addition 
to discovering small molecules targeting the ATPase activity, resources can be invested to discover molecules to 
inhibit key protein–protein interactions essential for the function of chromatin remodeling complexes. The inhibition 
of the BAF57–AR interaction is a successful example of this strategy, in prostate cancer cells (Link et al., 2008). 
Additional means to inhibit chromatin remodeling complexes with this approach can also include targeting essential 
subunit interactions within a remodeling complex. Another strategy to therapeutically regulate chromatin remodeling 
is to identify small molecules that can regulate the expression of genes encoding essential subunits of chromatin 
remodeling complexes. This has successfully been done to reexpress the BRM ATPase in cancer cell lines that have 
silenced its expression without a deletion (Gramling & Reisman, 2011; Gramling et al., 2011).  
 
 
5. Conclusions and future perspectives 
The role of histone modifications in governing cellular functions has not yet been fully understood. However, 
with increased research over the past decade, the importance of chromatin environment, especially histone post-
translational modifications and chromatin remodelers, in development and disease is being uncovered. Advances in 
our understanding of the natural history of CRC and the epigenetics of colon polyps and CRC has led to the 
development of epigenetic biomarker assays for CRC diagnosis, prognosis, and prediction of treatment response. The 
advances in understanding of the altered patterns of histone modifications and chromatin remodeling in CRC have 
demonstrated the potential of these altered patterns to be used as biomarkers for colon polyps and CRC. Continued 
investigation of these promising classes of biomarkers promises to lead to high performance assays that can be 
introduced into the clinical setting and used to prevent and manage patients with CRC.  
Histone modifications, such as methylation and acetylation, were detected in circulating nucleosomes in blood 
of patients with colorectal cancer, showing considerable potential as biomarkers. The combination of several histone 
marks rather than single histone marks is believed to further enhance sensitivity and specificity of cancer detection. 
Multiplex approaches could be utilized to assess the clinical relevance of such modification patterns. Large, 
prospective trials are needed to show their superiority or additive value to already existing protein and DNA tumor 
markers. 
Additionally, research in the field of histone PTMs and chromatin remodelers allows for the development of 
epigenetic silencing targeted therapies in CRC. Epigenetic agents, such as HDAC inhibitors, have undergone major 
preclinical investigations and extensive clinical trials, either alone or in combinations with conventional 
chemotherapeutic agents, for their efficacy to treat various types of solid cancers, including CRC. However, the 
current challenge is to find selective epigenetic agents that demethylate or acetylate specific target(s) or that interfere 
with chromatin remodelers, to reduce toxicity and improve the response to therapies.  
Further work in the next decade may gain deeper understanding of the global patterns of histone 
posttranslational modifications and their corresponding changes which will hopefully reveal many molecular targets 






Table 1 - chromatin remodelers found to have an altered expression in CRC and possibly associated with 









AJCC stage, depth of 
tumor invasion, distant 
metastasis, and histologic 
differentiation; more 
agressive, poor survival 
Sanchez-Tillo et al., 
2010; Watanabe et 
al., 2011; Shengtao 





and higher pT stage 
Network, 2012;  
Jones et al., 2012; 
Cajuso et al, 2014; 
Lee et al., 2016a;  Ye 
et al., 2014 
SMARCC2 decreased  Kim et al., 2013 
SMARCB1 decreased 
poor differentiation, liver 
metastasis and shorter 
patients' survival 
Pancione et al., 
2013 
CHD5 decreased  
Mokarram et al., 
2009; Fatemi et al., 
2015 
CHD7, CHD8 decreased  Tahara et al. (2014) 
CHD4 increased 
early disease recurrence 
and decreased overall 
survival 
Cai et al., 2014; Xia 
et al., 2017 
MTA1 increased 
decreased overall survival 
and poor clinical outcome 
Higashijma et al., 
2011 
SATB1 increased poor prognosis 
Mansour et al., 
2016;  Brocato et 
al., 2015 SATB2 decreased 
sensitive marker to 
distinguish CRC from 
other cancer types; 
reduced expression 
associated with poor 
prognosis 
Tip60/p400 decreased 
critical for the response to 
5-fluorouracil; marker for 
the malignancy of CRC 
Mattera et al., 2009; 
Chevillard-Briet et 
al., 2013 
HELLS decreased  Choi et al., 2015 





Table 2 - histone post-translational modifications and respective regulatory enzimes found to be altered in CRC 
and possibly associated with tumorigenesis and, in some cases, also associated with clinical outcomes. 
 
 Epigenetic modification/ gene of 
regulatory enzime 
Expression in CRC Clinical correlation Reference 
Histone 
acetylation 
H4K16ac decreased  
Fraga et al. 
(2005) 









Cyrus et al., 
2013; 
Ishihama et al., 
2007; Rönsch 
et al., 2011; 
Stypula-Cyrus 
et al., 2013 
HDAC4 decreased  
Bassett and 
Barnett, 2014 
HDAC5 increased/decreased  
Bassett and 
Barnett, 2014; 
Rönsch et al., 
2011; Stypula-
Cyrus et al., 
2013 
SIRT1 increased  




stages, metastasis and 
poor clinical outcome; 
increased survival 
Ishihama et al., 
2007; Huh et 
al., 2013 
MOF increased  Su et al., 2016 
Histone 
methylation 
H4K20me3 decrease  










Gezer et al., 
2013; Benard 
et al., 2014 
H3K4me3 increased/decreased  
Salz et al., 
2014; Lu et al., 
2014 
H3K27me3 increased/decreased 
poor prognosis ; 
metachronous liver 
metastasis 
Gezer et al., 
2015; Benard 
et al., 2014 
H3K79me2 increased poor prognosis 
Kryczek et al., 
2014 
Bmi1 increased 
advanced stages and 
agressive types 
Du et al., 2010 
EZH2 increased  




MLL2 increased highly invasive 
Kang et al, 
2007 
MLL4 increased  et al. (2010) 
SETD1A increased  




JARID1B increased  
Ohta et al., 
2013 
LSD1 increased 
correlated with TNM 
stage, lymph node 
infiltration and 
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